Denufosol

Verona Pharma and Nuance Pharma Announce $219 Million Strategic Collaboration to Develop and Commercialize Ensifentrine in Greater China

Retrieved on: 
Thursday, June 10, 2021
Branches of biology, Medical specialties, Anatomy, Cystic fibrosis, Lung disorders, Channelopathies, Respiratory therapy, Mucus, Nebulizer, Denufosol

Ensifentrine also activates the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), which is beneficial in reducing mucous viscosity and improving mucociliary clearance.

Key Points: 
  • Ensifentrine also activates the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), which is beneficial in reducing mucous viscosity and improving mucociliary clearance.
  • Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs.
  • The Company is evaluating nebulized ensifentrine in its Phase 3 clinical program ENHANCE (Ensifentrine as a Novel inHAled Nebulized COPD thErapy) for COPD maintenance treatment.
  • Since its inception in 2014, Nuance Pharma has assembled a portfolio of promising clinical-stage drug candidates for respiratory, pain and iron deficiency anemia.

Verona Pharma Completes Enrollment in Pilot Study of pMDI Ensifentrine in U.S. Patients Hospitalized with COVID-19

Retrieved on: 
Thursday, January 14, 2021
Branches of biology, Anatomy, Organ systems, Cystic fibrosis, Channelopathies, Mucus, Respiratory disease, Denufosol, Allergic bronchopulmonary aspergillosis

Ensifentrine also activates the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), which is beneficial in reducing mucous viscosity and improving mucociliary clearance.

Key Points: 
  • Ensifentrine also activates the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR), which is beneficial in reducing mucous viscosity and improving mucociliary clearance.
  • Ensifentrine has demonstrated significant and clinically meaningful improvements in both lung function and symptoms, including breathlessness, in Verona Pharmas Phase 2 clinical studies in patients with moderate to severe Chronic Obstructive Pulmonary Disease (COPD).
  • Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs.
  • Ensifentrine is being evaluated in a pilot clinical study in patients hospitalized with COVID-19 and has potential applications in cystic fibrosis, asthma and other respiratory diseases.

Corbus Pharmaceuticals Announces Phase 2b Study of Lenabasum for Treatment of Cystic Fibrosis Did Not Meet Primary Endpoint

Retrieved on: 
Tuesday, October 6, 2020
Medical specialties, Health, Cystic Fibrosis Foundation, Cystic fibrosis, Organ systems, Clinical endpoint, Cystic Fibrosis Canada, Denufosol

The CF-002 Phase 2b trial did not meet the primary endpoint of a statistically significant reduction in rate of new PEx per subject per 28 weeks.

Key Points: 
  • The CF-002 Phase 2b trial did not meet the primary endpoint of a statistically significant reduction in rate of new PEx per subject per 28 weeks.
  • Barbara White, M.D., Chief Medical Officer and Head of Research of Corbus, said, We are very disappointed that the study did not meet the primary endpoint.
  • We thank the participants, the staff at study sites, the Cystic Fibrosis Foundation, and the European Cystic Fibrosis Society Clinical Trials for their support and partnership throughout this study.
  • The Phase 2b CF study was funded in part by a Development Award for up to $25 Million from the Cystic Fibrosis Foundation.

AR-501 (Cystic Fibrosis) Enrolls First Subject in Phase 1/2a Clinical Trial for Treatment of Chronic Lung Infections in Cystic Fibrosis Patients

Retrieved on: 
Wednesday, December 12, 2018
RTT, Channelopathies, Cystic fibrosis, Cystic Fibrosis Foundation, Health, Medicine, Burkholderiales, Anatomy, Cystic Fibrosis Trust, Denufosol

The study will accrue 48 healthy adult volunteers and 48 cystic fibrosis patients from approximately 15 sites in the U.S.

Key Points: 
  • The study will accrue 48 healthy adult volunteers and 48 cystic fibrosis patients from approximately 15 sites in the U.S.
  • The Phase 1/2a trial is part of a collaboration with the Cystic Fibrosis Foundation, which hascommitted up to $7.5 million in funding through Phase 1/2a.
  • AR-501 is an inhaled formulation of gallium citrate that is being developed to treat chronic lung infections in cystic fibrosis patients.
  • AR-501(cystic fibrosis).AR-501 is an inhaled formulation of gallium citrate with broad-spectrum anti-infective activity being developed to treat chronic lung infections in cystic fibrosis patients.